Allianz Asset Management GmbH Sells 9,884 Shares of Veeva Systems Inc. $VEEV

Allianz Asset Management GmbH trimmed its stake in Veeva Systems Inc. (NYSE:VEEV) by 1.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 653,290 shares of the technology company’s stock after selling 9,884 shares during the period. Allianz Asset Management GmbH’s holdings in Veeva Systems were worth $145,834,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of VEEV. Vanguard Group Inc. raised its stake in shares of Veeva Systems by 3.1% in the third quarter. Vanguard Group Inc. now owns 15,429,231 shares of the technology company’s stock worth $4,596,522,000 after buying an additional 457,806 shares during the period. Alliancebernstein L.P. raised its stake in shares of Veeva Systems by 4.1% in the third quarter. Alliancebernstein L.P. now owns 5,941,631 shares of the technology company’s stock worth $1,770,071,000 after buying an additional 235,983 shares during the period. Principal Financial Group Inc. raised its stake in shares of Veeva Systems by 0.6% in the fourth quarter. Principal Financial Group Inc. now owns 3,870,293 shares of the technology company’s stock worth $863,978,000 after buying an additional 23,416 shares during the period. State Street Corp raised its stake in shares of Veeva Systems by 2.2% in the third quarter. State Street Corp now owns 3,503,730 shares of the technology company’s stock worth $1,043,796,000 after buying an additional 76,397 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of Veeva Systems by 4.8% in the third quarter. JPMorgan Chase & Co. now owns 3,476,258 shares of the technology company’s stock worth $1,035,622,000 after buying an additional 159,984 shares during the period. 88.20% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on VEEV. UBS Group decreased their price objective on Veeva Systems from $220.00 to $190.00 and set a “neutral” rating on the stock in a research note on Thursday, June 4th. BMO Capital Markets decreased their price objective on Veeva Systems from $220.00 to $175.00 and set a “market perform” rating on the stock in a research note on Thursday, June 4th. Mizuho decreased their price objective on Veeva Systems from $295.00 to $270.00 and set an “outperform” rating on the stock in a research note on Thursday, June 4th. Evercore reaffirmed an “outperform” rating and issued a $185.00 price objective on shares of Veeva Systems in a research note on Thursday, June 4th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $225.00 price objective on shares of Veeva Systems in a research note on Thursday, June 4th. Eighteen investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $250.96.

Key Stories Impacting Veeva Systems

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Veeva announced that UCB is unifying its global pharmacovigilance and safety operations on the Veeva Safety Suite, which should help validate the platform, deepen customer usage, and support future recurring revenue. UCB Unifies Global Pharmacovigilance Operations with Veeva Safety Suite
• Positive Sentiment: Analyst-focused articles highlighted Veeva’s bullish Wall Street view, including an average price target implying substantial upside and a positive trend in earnings estimate revisions, which can reinforce investor confidence. Wall Street Analysts Predict a 41.87% Upside in Veeva (VEEV): Here’s What You Should Know
• Positive Sentiment: Zacks also described Veeva as a strong momentum stock, suggesting the shares are benefiting from favorable technical and sentiment trends. Here’s Why Veeva Systems (VEEV) is a Strong Momentum Stock
• Neutral Sentiment: Coverage of Veeva’s Falcon and Vault AI products noted that the tools expand workflow automation in life sciences, but management expects AI revenue to remain immaterial in fiscal 2027, limiting the near-term financial impact. Veeva’s Falcon and Vault AI: When Could AI Become a Revenue Driver?
• Neutral Sentiment: Additional articles repeated the same AI and analyst themes, adding little new fundamental news for Veeva Systems. Veeva’s Falcon and Vault AI: When Could AI Become a Revenue Driver?

Veeva Systems Stock Performance

Shares of VEEV stock opened at $167.78 on Wednesday. The firm has a market capitalization of $27.40 billion, a PE ratio of 29.91, a PEG ratio of 0.74 and a beta of 0.95. The stock has a fifty day simple moving average of $165.84 and a two-hundred day simple moving average of $193.68. Veeva Systems Inc. has a 52-week low of $148.05 and a 52-week high of $310.50.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings data on Wednesday, June 3rd. The technology company reported $2.24 earnings per share for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. The firm had revenue of $882.95 million during the quarter, compared to analyst estimates of $857.73 million. Veeva Systems had a return on equity of 13.72% and a net margin of 28.37%.The business’s quarterly revenue was up 16.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.97 earnings per share. Veeva Systems has set its FY 2027 guidance at 9.050-9.050 EPS and its Q2 2027 guidance at 2.210-2.220 EPS. On average, sell-side analysts forecast that Veeva Systems Inc. will post 6.46 EPS for the current fiscal year.

Insider Buying and Selling at Veeva Systems

In other news, Director Priscilla Hung sold 750 shares of the firm’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $155.64, for a total transaction of $116,730.00. Following the completion of the transaction, the director owned 3,253 shares in the company, valued at $506,296.92. This trade represents a 18.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.60% of the stock is currently owned by insiders.

About Veeva Systems

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.